Brokerages Set Nyxoah S.A. (NASDAQ:NYXH) Target Price at $17.80

Nyxoah S.A. (NASDAQ:NYXH) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $17.80.

NYXH has been the subject of a number of analyst reports. HC Wainwright cut their price target on shares of Nyxoah from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, May 24th. Oppenheimer reduced their price objective on Nyxoah from $20.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 15th. Stifel Nicolaus decreased their price objective on shares of Nyxoah from $27.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, June 24th. Cantor Fitzgerald dropped their target price on shares of Nyxoah from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, May 15th. Finally, Piper Sandler upped their target price on shares of Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nyxoah stock. Iron Triangle Partners LP acquired a new stake in Nyxoah S.A. (NASDAQ:NYXH) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 253,025 shares of the company’s stock, valued at approximately $3,413,000. Nyxoah accounts for 0.3% of Iron Triangle Partners LP’s holdings, making the stock its 28th largest holding.

Nyxoah Stock Up 2.3 %

Shares of NYXH stock opened at $7.19 on Wednesday. Nyxoah has a one year low of $4.00 and a one year high of $20.00. The company has a quick ratio of 3.70, a current ratio of 3.94 and a debt-to-equity ratio of 0.13. The stock has a fifty day moving average price of $8.98 and a 200 day moving average price of $9.89.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.45). Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. The company had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.20 million. Research analysts anticipate that Nyxoah will post -1.72 EPS for the current fiscal year.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.